Key Highlights:
- EssilorLuxottica announced that its Essilor Stellest lenses are now the only US FDA market-authorized spectacle lenses for myopia control available in India, marking a significant step in addressing rising vision issues among children.
- Backed by clinical data, the lenses have shown to slow myopia progression by 71% over two years, offering a solution beyond standard corrective lenses, which do not control disease progression.
- With myopia projected to impact nearly 50% of urban children in India by 2050, the company plans to expand access across metro and emerging cities, while promoting early screening and awareness to improve long-term eye health outcomes.
Implications:
EssilorLuxottica is using Essilor Stellest to move India’s pediatric myopia market from simple correction to active control, positioning the lens as the only US FDA–authorized myopia‑control spectacle option currently available in the country and backing it with data showing a 71% average reduction in myopia progression over two years versus standard single‑vision lenses.
Commercially, this gives EssilorLuxottica a strong first‑mover advantage just as myopia rates climb, nearly 50% of urban Indian children are projected to be myopic by 2050, supporting premium pricing, closer partnerships with ophthalmologists and optometrists, and a national push around early screening and awareness as the company rolls Stellest out from metros into emerging Tier‑2 and Tier‑3 cities.
Source: EssilorLuxottica | Image: EssilorLuxottica
No Comment! Be the first one.